Perfint Healthcare Corporation, based in Chennai, India and U.S.A., announced the launch of MAXIO, the company’s integrated planning, navigation and robotic targeting system for CT Guided tumor ablation. The ground-breaking product was unvieled by Sam Pitroda, Chairman National Innovation Council and Advisor to the Prime Minister on Public Information Infrastructure and Innova-tion, at a gala event at the Oberoi in New Delhi on Saturday, 2 June where doctors gathered from across the country to witness the birth of this exciting product.
Commenting on his company’s latest innovation, Nandakumar Subburaman, CEO and founder of Per-fint stated, “Interventional Oncology and in specific Tumor Ablation is rapidly becoming an effective alternate to surgical treatment for cancer, globally. MAXIO brings the practice of Interventional Oncology to a whole new level.” He added, “Our goal was to create a solution that would make life-saving ablation procedures available to a greater number of cancer sufferers. To do that, we realized that the complex techniques used by interventional radiologists would have to be made simpler and more predictable. That’s what we’ve done with MAXIO”.
“Tumor ablation is an effective alternate to surgery for inoperable tumors. For example, only about 20% of the liver cancer patients are surgical candidates. Tumor Ablation is an image guided minimally invasive procedure in which devices such as needles are used to deliver thermal or other energy to de-stroy the tumor. Visualisation, planning and needle placement are key to successful tumor ablation. MAXIO helps clinicians visualise, plan and perform tumor ablation safely with consistent quality. said Guruswamy K, Director – New Products, Perfint Healthcare.
MAXIO combines Tumor visualisation in 3D and procedure planning with Robotic targeting that helps clinicians achieve consistent procedure quality. During the planning phase, clinicians can “see” the tu-mor and surrounding structures, determine the best approach to reach the tumor, select the appropriate number and type of energy probes, visualise estimated ablation volumes and determine the sequence of probe placement.
MAXIO’s robotic targeting system then helps the clinician advance the probes as planned, to reach the tumor safely. Once the ablation procedure has been performed, MAXIO’s visualization tools help cli-nicians to verify and extend the procedure if needed.
Perfint’s launch event was followed by hands-on workshops and lectures by expert Interventional Ra-diologists from around the world. Perfint Healthcare is an innovative medical device company focused on the development of robotic assisted technologies that simplify complex procedures and improve the standard of care provided to patients in need of interventional therapies.